MTAP deletions, which occur in approximately 10 to 30 percent of all cancers, lead to elevated levels of MTA in tumour cells and BAY 3713372 is designed to bind the PRMT5-MTA complex thus specifically ...

SOUTH SAN FRANCISCO, Calif., April 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted ...

MTAP deletions, which occur in approximately 10 to 30 percent of all cancers, lead to elevated levels of MTA in tumour cells and BAY 3713372 is designed to bind the PRMT5-MTA complex thus specifically ...

IDE397 is a potent and selective small molecule inhibitor targeting (MAT2A), in patients having solid tumors with MTAP-deletion. The prevalence of MTAP-deletion is estimated to be approximately 26 ...

"Loss of the MTAP gene occurs in a variety of tumor types, including those with few treatment options and poor prognosis, such as pancreatic cancer and glioblastoma," said Dominik Ruettinger ...

SOUTH SAN FRANCISCO, Calif., April 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted ...